Comparative Responses in Lung Function Measurements with Tiotropium in Adolescents and Adults, and Across Asthma Severities: A Post Hoc Analysis

Global Initiative for Asthma. Global strategy for asthma management and prevention (2019 report). 2019 [cited October 29, 2019]. https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf.

Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–38.

Francisco B, Ner Z, Ge B, Hewett J, Konig P. Sensitivity of different spirometric tests for detecting airway obstruction in childhood asthma. J Asthma. 2015;52(5):505–11.

Quanjer PH, Stanojevic S, Stocks J, Hall GL, Prasad KV, Cole TJ, et al. Changes in the FEV(1)/FVC ratio during childhood and adolescence: an intercontinental study. Eur Respir J. 2010;36(6):1391–9.

Szefler SJ, Murphy K, Harper T, Boner A, Laki I, Engel M, et al. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J Allergy Clin Immunol. 2017;140:1277–87.

Vogelberg C, Engel M, Laki I, Bernstein JA, Schmidt O, El Azzi G, et al. Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma. J Allergy Clin Immunol. 2018;6(6):2160–2162.e9.

Hamelmann E, Bateman ED, Vogelberg C, Szefler SJ, Vandewalker M, Moroni-Zentgraf P, et al. Tiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trial. J Allergy Clin Immunol. 2016;138(2):441–450.e8.

Hamelmann E, Bernstein JA, Vandewalker M, Moroni-Zentgraf P, Verri D, Unseld A, et al. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. Eur Respir J. 2017;49:1601100.

Kerstjens HA, Casale TB, Bleecker ER, Meltzer EO, Pizzichini E, Schmidt O, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med. 2015;3(5):367–76.

Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198–207.

Paggiaro P, Halpin DM, Buhl R, Engel M, Zubek VB, Blahova Z, et al. The effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids: a randomized controlled trial. J Allergy Clin Immunol Pract. 2016;4(1):104–113.e2.

Chanez P, Bourdin A. Histopathology and natural history of asthma. In: Castro M, Kraft M, editors. Clinical asthma. 1st ed. Mosby: Elsevier; 2008. p. 23–4.

Witt CA, Sheshadri A, Carlstrom L, Tarsi J, Kozlowski J, Wilson B, et al. Longitudinal changes in airway remodeling and air trapping in severe asthma. Acad Radiol. 2014;21(8):986–93.

Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016;(1):CD011721.

Chari VM, McIvor RA. Tiotropium for the treatment of asthma: patient selection and perspectives. Can Respir J. 2018;2018:3464960.

Meltzer EO, Berger WE. A review of the efficacy and safety of once-daily tiotropium Respimat 2.5 micrograms in adults and adolescents with asthma. Allergy Asthma Proc. 2018;39(1):14–26.